---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021086"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:19:07.920368+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax reports FY2023 net loss $209.4M; axatilimab PDUFA Aug 28, 2024; cash $600M through 2026

## Summary
- Net loss for FY2023: $209.4M ($2.98 per share) vs $149.3M ($2.46 per share) in 2022.
- Cash and investments: $600.5M as of Dec 31, 2023, expected to fund operations through 2026.
- BLA for axatilimab in chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.
- NDA for revumenib in R/R KMT2Ar acute leukemia submitted under RTOR; PDUFA date expected 1Q24.
- Enrollment in AUGMENT-101 mNPM1 cohort to complete late 1Q/early 2Q; topline data in 4Q24.

## SEC filing metadata
- accession: 0000950170-24-021086
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021086/0000950170-24-021086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021086/sndx-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021086
- JSON: https://secwatch.observer/filing/0000950170-24-021086.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021086.txt

## Key facts
- Earnings Releases
  Syndax Pharmaceuticals Inc reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 27, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017024021086/0000950170-24-021086-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.